Starting Pimavanserin earlier shows better outcomes for Parkinson’s psychosis

Hallucinations and delusions — collectively called psychosis — are serious non-motor complications in Parkinson’s disease. They greatly impact quality of life, increase caregiver burden, and often lead to hospitalisation or nursing home placement. Until recently, these symptoms were managed imperfectly, partly because many antipsychotic drugs worsened movement symptoms or cognition in people with Parkinson’s. Pimavanserin emerged as a specialised treatment, targeting serotonin receptors rather than dopamine, and thus offering an option that doesn’t interfere with motor control. A new report from NeurologyLive highlights findings presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders that patients who began pimavanserin within six months of the onset of psychosis symptoms saw greater improvements in their symptoms than those who started later. The study looked at a phase-3 trial of 95 patients (randomised to pimavanserin 34 mg daily or placebo for six weeks) and found that the earlier-treated group had higher response rates, including better scores on functional measures — activities of daily living, psychological and social functioning. These findings suggest that when psychosis is caught early and treatment is initiated promptly, outcomes are better. The practical implication is clear: delaying treatment may reduce the chance of full benefit. It emphasises the value of early recognition, prompt referral and treatment initiation. Equally important: pimavanserin was shown in previous safety analyses not to worsen the motor symptoms or cognition of people with Parkinson’s, which is a crucial consideration when treating psychosis in this population. What this means for people living with Parkinson’s If you or a loved one with Parkinson’s start to experience hallucinations (for example seeing things that are not there) or delusions (false beliefs, for example a sense of someone being unfaithful), this study suggests it’s wise to act sooner rather than later. Early discussion with your Parkinson’s specialist or neurologist about whether pimavanserin might be suitable could improve the chances of better functional outcome. Because the data indicate higher effectiveness when treatment begins early, catching psychosis signs quickly — and not waiting until the situation worsens — may make a real difference. At the same time, it is important to recognise that while pimavanserin offers a more targeted and safer option than older antipsychotics, it is not a guaranteed cure. Psychosis in Parkinson’s is rarely resolved overnight, and treatment should form part of a comprehensive care plan that includes medication review (sometimes reducing causative influences), non-drug interventions, monitoring for side-effects and support for the person and their carers. So for families, the takeaway is one of cautious optimism: yes, there is a good treatment option, and starting early matters. But the broader challenge remains: recognising psychosis early, accessing a specialist who knows about the latest therapies, and integrating that therapy into the overall Parkinson’s care plan.